Astellas Pharma

Pharma / Pharmaceuticals, Healthcare

Founded: 2005 | Country: Japan | Ticker: ALPMY | ISIN: JP3942400007 | Rate: 1500

Info

Overview Core Facts Blog Ratings Executives My Comments

Analytics

Company Q&A Industry Q&A Competitors Stock Swings SWOT PEST Porter's Five Forces Score Positive Risks Revenue Segmentation

Financials

Income Statement Balance Sheet Cash Flow Statement

Ratios

Financial Ratios Financial Growth Enterprise Value Key Metrics Dividends

Tools

Due Diligence

Resources

News Clusters SEC Filings Stock Split History Press Releases Insider Trades Owner Earnings Earnings Calendar Web Reports

Risks

1. Regulatory uncertainty: As with any pharmaceutical company, Astellas Pharma India Private Limited is subject to the risk of regulatory changes in the health care industry. Changes in regulations may affect pricing, product approvals, and access to customers.

2. Reimbursement risk: Reimbursement policies can limit the sale of certain drugs or applications for reimbursement. This could affect Astellas Pharma India Private Limited’s revenue and profitability.

3. Intellectual property risk: Investing significant resources into developing and protecting the company’s drug molecules is essential to Astellas Pharma India Private Limited’s success. Intellectual property rights are important safeguards, however, there is a risk of competitors copying products or infringing on such rights.

4. Competitive risks: There may be competition from smaller, disruptive innovators as well as large pharmaceutical companies, both with established operations in India.

5. Technological risk: Astellas Pharma India Private Limited is subject to continuous changes and advancements in technology. New technologies must be leveraged for efficient operations and to remain competitive.

6. Supply chain risks: A disruption in the supply chain could adversely affect operations. It is important that Astellas Pharma India Private Limited has a reliable situation with third-party sources to ensure a constant flow of raw materials.

What is special about us?

Imprint

Disclaimer

×
Disclaimer

InsightfulValue is an independent platform dedicated to value investing research. The information provided on this website is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice.
We are not financial advisors, investment consultants, or licensed consultants. Our analyses, insights, and criteria are based on principles learned from renowned value investors such as Benjamin Graham, Warren Buffett, and Charlie Munger, but they should not be considered personalized investment recommendations.
Investing in financial markets carries risks, and past performance is not indicative of future results. Users of this website should conduct their own due diligence and consult with a qualified professional before making any financial or investment decisions. InsightfulValue assumes no liability for any financial losses or decisions made based on the information provided on this site.
By using this website, you acknowledge and accept that all investments involve risk and that InsightfulValue does not guarantee any financial outcomes.

Legal

Due Diligence

This feature is only available for users with Insider or Visionary license. Please, signup or login.